CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
- Citi's 14th Annual
Biotech Conferencein Boston, MA. Myovant will host meetings with investors at the conference on Wednesday, September 4, 2019.
- Baird 2019 Global Healthcare Conference in New
York, NY. Lynn Seely, MD, Myovant's President and Chief Executive Officer, will participate in a fireside chat on Thursday, September 5, 2019, in a session scheduled to begin at 2:35 p.m. ET.
- BioCentury’s 26th Annual Newsmakers in the
Biotech Industry Conferencein New York, NY. Lynn Seely, MD, will present on Friday, September 6, 2019, in a session scheduled to begin at 9:00 a.m. ET.
A live webcast of the Baird 2019 Global Healthcare Conference will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay of the webcast will be available at the same location for 30 days following the conference.
About Myovant Sciences
Myovant Sciences aspires to be the leading healthcare company focused on innovative treatments for women's health and prostate cancer. Myovant Science’s lead product candidate is relugolix, an oral, once-a-day small molecule that acts as a GnRH receptor antagonist.
Chief Financial Officer
Source: Myovant Sciences, Inc.